A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Phase 4 Completed 99 enrolled Bausch & Lomb Incorporated

NaSingle-groupOpen-labelTreatment

Summary

An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Timeline

Start: 2024-02-28
Primary completion: 2024-06-17
Completion: 2024-06-17

Outcome

Met primary endpoint

paper The primary endpoint was met: mean (SD) overall symptom severity decreased significantly from 72.1 (17.0) at baseline to 27.8 (22.3) PMID 39985746 ↗

Publications

Bacharach J, Kannarr SR, Verachtert A, Gupta PK, Razeen M, Cavet ME, Vittitow JL, Lang J, Chester TM, Ziemanski JF, White DE. Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study. Ophthalmol Ther. 2025 Apr;14(4):693-704. doi: 10.1007/s40123-025-01097-z. Epub 2025 Feb 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Perfluorohexyloctane	Unknown	—	Other